<DOC>
	<DOCNO>NCT02256189</DOCNO>
	<brief_summary>To evaluate effect DPP-4 inhibition glucagon counter-regulatory mechanism moderate hypoglycemia metformin-treated subject T2DM</brief_summary>
	<brief_title>Sitagliptin Glucagon Counterregulation</brief_title>
	<detailed_description>The glucagon response mild ( 3.0 mmol/l ) hypoglycemia without DPP-4 inhibition sitagliptin evaluate elderly subject metformin treat type 2 diabetes explore whether DPP-4 inhibition affect glucagon counter-regulation .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Written consent give . 2 . Patients metformin treat T2DM ( metformin dose &gt; 0,5 g/day stable precede 3 month ) 3 . Age &gt; 65 year . 4 . HbA1c 6.08.5 % ( 4367 mmol/mol ; inclusive ) visit 1 . 5 . Ability complete study 1 . A history secondary form diabetes , e.g. , Cushing 's syndrome acromegaly . 2 . Type 2 diabetes , positive GAD antibodies 3. eGFR &lt; 60 ml/min 4 . Acute infection may affect blood glucose control within 4 week prior visit 1 5 . Any history recent ( &lt; 2 week ) recurrent severe hypoglycemic episode . 6 . Liver disease cirrhosis chronic active hepatitis 7 . History coronary heart disease heart failure class III IV 8 . Donation one unit ( 500 ml ) blood , significant blood loss equal least one unit blood within past 2 week blood transfusion within past 8 week . 9 . Treatment growth hormone chronic oral parenteral corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week prior visit 1 . 10 . Use investigational drug visit 1 within 30 day visit 1 , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>